TLR Ligand-Peptide Conjugate Vaccines. Toward Clinical Application.

Advances in Immunology

Volumn 114, Issue , 2012, Pages 177-201

  Zom, Gijs G P ^a   Khan, Selina ^a   Filippov, Dmitri V ^b   Ossendorp, Ferry ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Anti tumor immunity; Conjugate; Dendritic cell; Immune therapy; Ligands; Pattern recognition receptor; T cells; Toll like receptor

Indexed keywords

ADJUVANT; AGATOLIMOD; AMINOSUGAR; ANTIGEN; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; EPITOPE; FUSION PEPTIDE; GAG PROTEIN; LIGAND; LIPOPROTEIN; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA VACCINE; OVALBUMIN; PAM3CSK4; PATTERN RECOGNITION RECEPTOR; PEPTIDE; PEPTIDE VACCINE; PROTEIN E7; RESIQUIMOD; SLP VACCINE; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2 LIGAND; TOLL LIKE RECEPTOR 7 LIGAND; TOLL LIKE RECEPTOR 9 LIGAND; TOLL LIKE RECEPTOR LIGAND; TOLL LIKE RECEPTOR LIGAND PEPTIDE CONJUGATE VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CANCER THERAPY; CELL ACTIVATION; DENDRITIC CELL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; UTERINE CERVIX CANCER;

EID: 84858767031     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-396548-6.00007-X     Document Type: Chapter

References (114)

1. Ahmad-Nejad P., Hacker H., et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 2002, 32(7):1958-1968.
2. Akira S., Uematsu S., et al. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
3. Anderson K.V., Jurgens G., et al. Establishment of dorsal-ventral polarity in the Drosophila embryo: Genetic studies on the role of the Toll gene product. Cell 1985, 42(3):779-789.
4. Asai Y., Makimura Y., et al. Toll-like receptor 2-mediated dendritic cell activation by a Porphyromonas gingivalis synthetic lipopeptide. J. Med. Microbiol. 2007, 56(Pt 4):459-465.
5. Asano J., Tada H., et al. Nucleotide oligomerization binding domain-like receptor signaling enhances dendritic cell-mediated cross-priming in vivo. J. Immunol. 2010, 184(2):736-745.
6. Banchereau J., Briere F., et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
7. Baumann C.L., Aspalter I.M., et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J. Exp. Med. 2010, 207(12):2689-2701.
8. Bennett S.R., Carbone F.R., et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. 1997, 186(1):65-70.
9. Bennett S.R., Carbone F.R., et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393(6684):478-480.
10. Bryant C.E., Spring D.R., et al. The molecular basis of the host response to lipopolysaccharide. Nat. Rev. Microbiol. 2010, 8(1):8-14.
11. Buonerba C., Ferro M., et al. Sipuleucel-T for prostate cancer: The immunotherapy era has commenced. Expert Rev. Anticancer Ther. 2011, 11(1):25-28.
12. Chaturvedi A., Pierce S.K. How location governs toll-like receptor signaling. Traffic 2009, 10(6):621-628.
13. Chen C.M., Gong Y., et al. Reciprocal cross-talk between Nod2 and TAK1 signaling pathways. J. Biol. Chem. 2004, 279(24):25876-25882.
14. Cho H.J., Takabayashi K., et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 2000, 18(5):509-514.
15. Daftarian P., Sharan R., et al. Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine 2005, 23(26):3453-3468.
16. Daftarian P., Mansour M., et al. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006, 24(24):5235-5244.
17. De Haan L., Hearn A.R., et al. Enhanced delivery of exogenous peptides into the class I antigen processing and presentation pathway. Infect. Immun. 2002, 70(6):3249-3258.
18. de Jong A., van Poelgeest M.I., et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 2004, 64(15):5449-5455.
19. de Vos van Steenwijk P.J., Heusinkveld M., et al. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res. 2010, 70(7):2707-2717.
20. Dennehy K.M., Ferwerda G., et al. Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur. J. Immunol. 2008, 38(2):500-506.
21. Deres K., Schild H., et al. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989, 342(6249):561-564.
22. Feltkamp M.C., Smits H.L., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 1993, 23(9):2242-2249.
23. Flinsenberg T.W., Compeer E.B., et al. Antigen cross-presentation: Extending recent laboratory findings to therapeutic intervention. Clin. Exp. Immunol. 2011, 165(1):8-18.
24. Franchi L., Warner N., et al. Function of Nod-like receptors in microbial recognition and host defense. Immunol. Rev. 2009, 227(1):106-128.
25. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 2004, 4(1):46-54.
26. Fritz J.H., Girardin S.E., et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur. J. Immunol. 2005, 35(8):2459-2470.
27. Gay N.J., Gangloff M. Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem. 2007, 76:141-165.
28. Geiger J.D., Hutchinson R.J., et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001, 61(23):8513-8519.
29. Goodridge H.S., Shimada T., et al. Differential use of CARD9 by dectin-1 in macrophages and dendritic cells. J. Immunol. 2009, 182(2):1146-1154.
30. Gross O., Poeck H., et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009, 459(7245):433-436.
31. Gursel M., Gursel I., et al. CXCL16 influences the nature and specificity of CpG-induced immune activation. J. Immunol. 2006, 177(3):1575-1580.
32. Hedl M., Abraham C. Distinct roles for Nod2 protein and autocrine interleukin-1{beta} in muramyl dipeptide-induced mitogen-activated protein kinase activation and cytokine secretion in human macrophages. J. Biol. Chem. 2011, 286(30):26440-26449.
33. Heit A., Maurer T., et al. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J. Immunol. 2003, 170(6):2802-2805.
34. Heit A., Schmitz F., et al. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol. 2005, 174(7):4373-4380.
35. Hohlich B.J., Wiesmuller K.H., et al. Induction of an antigen-specific immune response and partial protection of cattle against challenge infection with foot-and-mouth disease virus (FMDV) after lipopeptide vaccination with FMDV-specific B-cell epitopes. J. Gen. Virol. 2003, 84(Pt 12):3315-3324.
36. Ingale S., Wolfert M.A., et al. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chembiochem 2009, 10(3):455-463.
37. Itoh K., Watanabe A., et al. The clathrin-mediated endocytic pathway participates in dsRNA-induced IFN-beta production. J. Immunol. 2008, 181(8):5522-5529.
38. Jackson D.C., Lau Y.F., et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 2004, 101(43):15440-15445.
39. Jeannin P., Bottazzi B., et al. Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity 2005, 22(5):551-560.
40. Jin M.S., Lee J.O. Structures of TLR-ligand complexes. Curr. Opin. Immunol. 2008, 20(4):414-419.
41. Kast W.M., Roux L., et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 1991, 88(6):2283-2287.
42. Kawai T., Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 2009, 21(4):317-337.
43. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 2010, 11(5):373-384.
44. Kenter G.G., Welters M.J., et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 2008, 14(1):169-177.
45. Kenter G.G., Welters M.J., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 2009, 361(19):1838-1847.
46. Khan S., Bijker M.S., et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 2007, 282(29):21145-21159.
47. Khan S., Weterings J.J., et al. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol. Immunol. 2009, 46(6):1084-1091.
48. Klinman D.M., Currie D., et al. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 2004, 199:201-216.
49. Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 1997, 102(5A):3-8.
50. Kufer T.A., Sansonetti P.J. Sensing of bacteria: NOD a lonely job. Curr. Opin. Microbiol. 2007, 10(1):62-69.
51. Latz E., Schoenemeyer A., et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 2004, 5(2):190-198.
52. Lee H.K., Dunzendorfer S., et al. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity 2006, 24(2):153-163.
53. Lemaitre B., Nicolas E., et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86(6):973-983.
54. Loo Y.M., Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011, 34(5):680-692.
55. Lutzner N., Kalbacher H. Quantifying cathepsin S activity in antigen presenting cells using a novel specific substrate. J. Biol. Chem. 2008, 283(52):36185-36194.
56. Makimura Y., Asai Y., et al. Correlation between chemical structure and biological activities of Porphyromonas gingivalis synthetic lipopeptide derivatives. Clin. Exp. Immunol. 2006, 146(1):159-168.
57. Mansour M., Pohajdak B., et al. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. J. Transl. Med. 2007, 5:20.
58. Maurer T., Heit A., et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur. J. Immunol. 2002, 32(8):2356-2364.
59. Melief C.J., Toes R.E., et al. Strategies for immunotherapy of cancer. Adv. Immunol. 2000, 75:235-282.
60. Mellman I., Steinman R.M. Dendritic cells: Specialized and regulated antigen processing machines. Cell 2001, 106(3):255-258.
61. Metzger J., Jung G., et al. Lipopeptides containing 2-(palmitoylamino)-6,7-bis(palmitoyloxy) heptanoic acid: Synthesis, stereospecific stimulation of B-lymphocytes and macrophages, and adjuvanticity in vivo and in vitro. J. Med. Chem. 1991, 34(7):1969-1974.
62. Meylan E., Tschopp J. The RIP kinases: Crucial integrators of cellular stress. Trends Biochem. Sci. 2005, 30(3):151-159.
63. Mocsai A., Ruland J., et al. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat. Rev. Immunol. 2010, 10(6):387-402.
64. Monie T.P., Bryant C.E., et al. Activating immunity: Lessons from the TLRs and NLRs. Trends Biochem. Sci. 2009, 34(11):553-561.
65. Obert M., Pleuger H., et al. Protection of mice against SV40 tumours by Pam3Cys, MTP-PE and Pam3Cys conjugated with the SV40 T antigen-derived peptide, K(698)-T(708). Vaccine 1998, 16(2-3):161-169.
66. Osorio F., Reis e Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 2011, 34(5):651-664.
67. Ossendorp F., Mengede E., et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 1998, 187(5):693-702.
68. Ossendorp F., Toes R.E., et al. Importance of CD4(+) T helper cell responses in tumor immunity. Immunol. Lett. 2000, 74(1):75-79.
69. Ossendorp F., Fu N., et al. Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. J. Immunol. 2005, 174(12):7815-7822.
70. Palefsky J.M. Human papillomavirus-related tumors. AIDS 2000, 14(Suppl 3):S189-S195.
71. Palefsky J.M., Holly E.A. Chapter 6: Immunosuppression and co-infection with HIV. J. Natl. Cancer Inst. Monogr. 2003, (31):41-46.
72. Pedicord V.A., Montalvo W., et al. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc. Natl. Acad. Sci. USA 2011, 108(1):266-271.
73. Petterson T., Jendholm J., et al. Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. J. Leukoc. Biol. 2011, 89(2):177-187.
74. Poltorak A., He X., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998, 282(5396):2085-2088.
75. Ribas A., Camacho L.H., et al. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J. Transl. Med. 2010, 8:89.
76. Ridge J.P., Di Rosa F., et al. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393(6684):474-478.
77. Rosenberg S.A., Yang J.C., et al. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004, 10(9):909-915.
78. Rosenblatt J., Glotzbecker B., et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 2011, 34(5):409-418.
79. Sasadeusz J., Kelly H., et al. Abnormal cervical cytology in bone marrow transplant recipients. Bone Marrow Transplant. 2001, 28(4):393-397.
80. Schoenberger S.P., Toes R.E., et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393(6684):480-483.
81. Schultz E.S., Schuler-Thurner B., et al. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J. Immunol. 2004, 172(2):1304-1310.
82. Schuurhuis D.H., Laban S., et al. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J. Exp. Med. 2000, 192(1):145-150.
83. Schuurhuis D.H., Ioan-Facsinay A., et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J. Immunol. 2002, 168(5):2240-2246.
84. Segura E., Villadangos J.A. Antigen presentation by dendritic cells in vivo. Curr. Opin. Immunol. 2009, 21(1):105-110.
85. Shamsul H.M., Hasebe A., et al. The Toll-like receptor 2 (TLR2) ligand FSL-1 is internalized via the clathrin-dependent endocytic pathway triggered by CD14 and CD36 but not by TLR2. Immunology 2010, 130(2):262-272.
86. Shirota H., Sano K., et al. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J. Immunol. 2001, 167(1):66-74.
87. Shortman K., Heath W.R. The CD8+ dendritic cell subset. Immunol. Rev. 2010, 234(1):18-31.
88. Speiser D.E., Lienard D., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005, 115(3):739-746.
89. Spohn R., Buwitt-Beckmann U., et al. Synthetic lipopeptide adjuvants and Toll-like receptor 2-Structure-activity relationships. Vaccine 2004, 22(19):2494-2499.
90. Steinman R.M. Dendritic cells in vivo: A key target for a new vaccine science. Immunity 2008, 29(3):319-324.
91. Tada H., Aiba S., et al. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect. Immun. 2005, 73(12):7967-7976.
92. Takada H., Galanos C. Enhancement of endotoxin lethality and generation of anaphylactoid reactions by lipopolysaccharides in muramyl-dipeptide-treated mice. Infect. Immun. 1987, 55(2):409-413.
93. Takada H., Yokoyama S., et al. Enhancement of endotoxin activity by muramyldipeptide. J. Endotoxin Res. 2002, 8(5):337-342.
94. Takahashi Y., Isuzugawa K., et al. Up-regulation of NOD1 and NOD2 through TLR4 and TNF-alpha in LPS-treated murine macrophages. J. Vet. Med. Sci. 2006, 68(5):471-478.
95. Takeuchi O., Akira S. MDA5/RIG-I and virus recognition. Curr. Opin. Immunol. 2008, 20(1):17-22.
96. Tighe H., Takabayashi K., et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 2000, 106(1 Pt 1):124-134.
97. Toes R.E., Blom R.J., et al. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 1996, 156(10):3911-3918.
98. Toes R.E., Offringa R., et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 1996, 93(15):7855-7860.
99. Uehara A., Yang S., et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell. Microbiol. 2005, 7(1):53-61.
100. Vambutas A., DeVoti J., et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005, 23(45):5271-5280.
101. van den Broeke L.T., Daschbach E., et al. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J. Immunol. 2003, 171(11):5842-5852.
102. van Montfoort N., Camps M.G., et al. Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc. Natl. Acad. Sci. USA 2009, 106(16):6730-6735.
103. van Poelgeest M.I., van Seters M., et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin. Cancer Res. 2005, 11(14):5273-5280.
104. Welters M.J., Kenter G.G., et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 2008, 14(1):178-187.
105. Welters M.J., Kenter G.G., et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl. Acad. Sci. USA 2010, 107(26):11895-11899.
106. Weterings J.J., Khan S., et al. Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: Towards synthetic epitope-based vaccines. Bioorg. Med. Chem. Lett. 2006, 16(12):3258-3261.
107. Wille-Reece U., Wu C.Y., et al. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol. 2005, 174(12):7676-7683.
108. Wu C.C., Hayashi T., et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc. Natl. Acad. Sci. USA 2007, 104(10):3990-3995.
109. York I.A., Goldberg A.L., et al. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol. Rev. 1999, 172:49-66.
110. Zarour H.M., Ferrone S. Cancer immunotherapy: Progress and challenges in the clinical setting. Eur. J. Immunol. 2011, 41(6):1510-1515.
111. Zeng W., Horrocks K.J., et al. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building. J. Biol. Chem. 2011, 286(15):12944-12951.
112. Zhang X., Chentoufi A.A., et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2009, 2(2):129-143.
113. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2002, 2(5):342-350.
114. Zwaveling S., Ferreira Mota S.C., et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 2002, 169(1):350-358.